The disclosure relates to the use a polyunsaturated fatty acid (PUFA) derivative of general formula I in the manufacture of a medicament for topical treatment of skin inflammation in a mammal. The skin inflammation may be caused by atopic eczema, contact dermatitis, psoriasis, uremic pruritis electromagnetic radiation. The medicament may be co-administered with a corticosteroid.